Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-
 
WKN: A14SDD / Name: Blueprint / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Blueprint Medicines Corp Stock

So far the community has only identified positive things for Blueprint Medicines Corp stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Blueprint Medicines Corp in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Blueprint Medicines Corp vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Blueprint Medicines Corp - - - - - - -
Ionis Pharmaceuticals Inc. 1.360% 7.292% 8.284% 38.366% -24.220% 44.056% 58.462%
United Therapeutics 1.140% 0.359% -4.315% 66.320% 4.821% 112.074% 163.471%
Novocure Ltd 3.220% -2.680% 6.509% 43.726% 31.363% -48.209% -86.735%

News

Pegasystems Highlights AI Push, Sales Reset After Soft ACV GrowthPhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Pegasystems Highlights AI Push, Sales Reset After Soft ACV Growth

Key Points

ExxonMobil Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
ExxonMobil Q2 Earnings Call Highlights

ExxonMobil (NYSE:XOM) reported second-quarter earnings of $14.5 billion and cash flow from operations of $23.6 billion, as the company said

Applied Digital Is Building a $36 Billion AI Real Estate EmpirePhoto, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
Applied Digital Is Building a $36 Billion AI Real Estate Empire

Key Points